(Press-News.org) According to a recent study, 44% of people with chronic conditions who responded to a population-based survey experienced medication-related burden (MRB). The burden was most common among people with diabetes, heart disease, rheumatic disease or some other musculoskeletal disorder. The greatest burden was caused by factors associated with health care, such as fragmented care and the cost of medicines, as well as adverse drug reactions or concerns about them.
“Other factors linked with MRB were poor health status, limits on functional capacity and low income,” says Pharmacist and Doctoral Researcher Heidi Mikkola from the School of Pharmacy at the University of Eastern Finland. Mikkola also works as a researcher at the Finnish Medicines Agency Fimea.
Medication therapy plays an important role in treating many chronic conditions, but it can also cause significant burden in a patient’s daily life. MRB refers to the psychological, social and practical burden experienced by the patient in connection with using medicines. MRB can reduce adherence to treatment, lower patients’ quality of life and lead to increased healthcare costs.
“Identifying the illnesses and patient groups that involve the greatest risk of MRB will allow healthcare to allocate support and resources more efficiently,” says Mikkola.
The study shows that experiencing MRB is a common phenomenon at the population level and its prevalence varies across different chronic conditions. Healthcare professionals should take patient perspectives and the different dimensions of MRB into account so that treatment can be planned in an individual and patient-oriented manner.
The study performed by the University of Eastern Finland and Fimea utilised data from the 2021 Medicines Barometer population survey. The Medicines Barometer is a survey aimed at the population to investigate Finns' views and experiences regarding medicines. The population survey is conducted by Fimea every two years. The study utilised the survey responses of 1,323 Finns who had at least one diagnosed chronic condition and used prescription medications. The peer-reviewed research results were published in BMC Health Services Research. The study is part of Mikkola’s doctoral dissertation.
END
Nearly half of Finns with chronic conditions find medication therapy a burden
2025-10-20
ELSE PRESS RELEASES FROM THIS DATE:
Do animals fall for optical illusions? What fish and birds can teach us about perception
2025-10-20
Have you ever looked at two circles of exactly the same size and sworn one was larger? If so, your eyes have been tricked by the Ebbinghaus illusion, a classic example of how context can shape what we see. Place a circle among other smaller circles, and it seems bigger; place it among larger ones, and it shrinks before our eyes. This illusion fascinates psychologists because it reveals that perception is not a mirror of the outside world but a clever construction of the brain.
But here is the question that inspired our study: do other animals fall for the same tricks? If a tiny fish or a bird perceives ...
New guideline emphasizes conversations about mood, mental health between patients and clinicians
2025-10-20
Depression is a mental illness, and support for depression can improve emotions, thoughts, and well-being. A new guideline from the Canadian Task Force on Preventive Health Care recommends that patients aged 18 and older talk to their health care providers about depression rather than undergo routine screening with standard tools, like questionnaires. The guideline is published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.250237.
In Canada, depression is common, with about 1 in 10 people (without bipolar disorder) experiencing depression in their lifetimes. It negatively affects how a person ...
Children’s Hospital of Philadelphia researchers observe significant reduction in diagnosis of food allergies following expert guidelines encouraging early peanut exposure
2025-10-20
Philadelphia, October 20, 2025 – Peanuts represent one of the most common causes of immunoglobulin E (IgE)-mediated, or anaphylactic, food allergies in children, yet a landmark study found that early introduction of peanut to infants may lower their risk of developing this allergy. Now, a new study from researchers from Children’s Hospital of Philadelphia (CHOP) has shown that the rates of diagnosis of peanut and other IgE-mediated food allergies have declined since the adoption of guidelines encouraging early introduction practices.
The findings, published today ...
ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma
2025-10-19
VT3989 is a first-in-class YAP-TEAD inhibitor from Vivace Therapeutics that is currently in Phase I/II trials for patients with advanced solid tumors, with a focus on refractory mesothelioma
In this trial, VT3989 demonstrated notable antitumor activity, with a disease control rate of 86% at the clinically optimized dosing levels
These data provide the first clinical proof-of-concept for effectively drugging the Hippo-YAP-TEAD pathway
VT3989 was awarded Orphan Drug Designation and Fast Track Designation for the treatment of mesothelioma by the FDA
BERLIN, OCTOBER 19, 2025 ― The first-in-class YAP-TEAD inhibitor ...
Study finds COVID-19 mRNA vaccine sparks immune response to fight cancer
2025-10-19
Patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who did not get the vaccine, researchers have found.
The observation by researchers at the University of Florida and the University of Texas MD Anderson Cancer Center is a defining moment in a decade-plus of research testing mRNA-based therapeutics designed to “wake up” the immune system against cancer. Building on a previous UF study, the observation also marks a significant step toward a long-awaited universal cancer vaccine to ...
ESMO 2025: mRNA-based COVID vaccines generate improved responses to immunotherapy
2025-10-19
Cancer patients who received mRNA COVID vaccines within 100 days of starting immunotherapy were twice as likely to be alive three years after treatment as those who never received a vaccine
These findings have prompted a randomized Phase III trial to determine if mRNA COVID vaccines should be part of the standard of care for this type of therapy
If validated, findings could significantly increase the number of patients who benefit from immunotherapy
BERLIN, OCTOBER 19, 2025 ― Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice as likely to be alive three years after beginning ...
Drug combo cuts risk of death in advanced prostate cancer by 40%
2025-10-19
Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%.
The combination therapy, which adds a drug called enzalutamide to commonly prescribed hormone therapy, reduced deaths in patients with recurrent prostate cancer after surgery or radiation for whom other treatments are no longer an option. The trial results were published in The New England Journal of Medicine (NEJM) with simultaneous presentation during the European Society for Medical Oncology Congress (ESMO) Oct. 19 in Berlin.
“After ...
ADC improves outcomes for patients with advanced triple-negative breast cancer who are ineligible for immune checkpoint inhibitors
2025-10-19
BERLIN October 19, 2025 – Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan compared to standard chemotherapy. These findings, which stem from the ASCENT-03 trial in triple-negative breast cancer co-led by investigators at Dana-Farber Cancer Institute, are presented today at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. They are also published simultaneously in the New England Journal ...
Novel treatment combination improves progression-free survival in metastatic, estrogen-receptor-positive HER-2-negative breast cancer
2025-10-18
BERLIN October 18, 2025 – Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation selective estrogen receptor degrader and full antagonist, compared to a standard combination approach. These findings, from the phase 3 evERA Breast Cancer study, are presented today by Dr. Erica Mayer of Dana-Farber Cancer Institute at the annual meeting of the European Society for Medical Oncology (ESMO) in Berlin, Germany.
Tumors that express the estrogen receptor (ER) account for roughly 70% ...
ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumors and improves symptoms in patients
2025-10-18
Pheochromocytoma and paraganglioma (PPGL) are rare, hard-to-treat neuroendocrine tumors that form in the adrenal glands or in the extra-adrenal paraganglia
Study found belzutifan shrank tumors and improved symptoms without surgery
Belzutifan is the first oral and only FDA-approved treatment for patients with advanced, inoperable, or metastatic PPGL
FDA granted approval for treating PPGL in May 2025 based on these trial results
BERLIN, OCTOBER 18, 2025 – A multicenter Phase II clinical ...